Therapeutic Nanosystems for Oncology Nanomedicine

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2012 Aug 3

PMID 22855194

Citations 8

Authors

A S Goncalves

A S Macedo

E B Souto

Affiliations

Soon will be listed here.

Abstract

Cancer is a complex disease which includes many pathologies featuring abnormal growth of healthy cells, invasion and metastization. Cellular uncontrolled growth increases the amount of abnormal cells, these cells reach the blood stream and other healthy tissues giving rise to secondary tumors. Even though great progresses have been made in understanding cancer aetiology and in the development of new anticancer drugs, cancer still remains one of the leading causes of death worldwide. Most common cancers include breast cancer, lung cancer, colorectal cancer and brain cancer. Conventional chemotherapeutics have proven to be inefficient in cancer treatment due to lack of specificity and poor drug accumulation in tumors. In addition, they cause severe side effects. Available treatments must be prolonged on time to achieve some therapeutic effect; however, this often leads to the development of multidrug resistance by tumor cells. Nanotechnology platforms are, therefore, being exploited as potential alternatives. Nanosystems have been reported to target and deliver the drug in situ to selectively kill cancer cells, decreasing toxicity on healthy organs and tissues as well as side effects. Furthermore, some nanosystems have been reported to overcome tumor resistance, at least to some extent. Over the years several nanosystems have been proposed to diagnose and treat cancers, such as dendrimers, polymeric micelles, superparamagnetic iron oxide cores, gold nanoparticles, liposomes and other lipid nanoparticles. Due to their small size and biocompatibility, they can reach the target site without being detected by the immune system and suffer cellular uptake or deliver the drug in the tumor vicinity.

Citing Articles

D2B-Functionalized Gold Nanoparticles: Promising Vehicles for Targeted Drug Delivery to Prostate Cancer.

Sarkis M, Minassian G, Mitri N, Rahme K, Fracasso G, El Hage R ACS Appl Bio Mater. 2023; 6(2):819-827.

PMID: 36755401 PMC: 9945086. DOI: 10.1021/acsabm.2c00975.

Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.

Majumder J, Minko T Adv Ther (Weinh). 2020; 4(2):2000203.

PMID: 33173809 PMC: 7646027. DOI: 10.1002/adtp.202000203.

Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU.

Souto E, Silva G, Dias-Ferreira J, Zielinska A, Ventura F, Durazzo A Pharmaceutics. 2020; 12(2).

PMID: 32053962 PMC: 7076491. DOI: 10.3390/pharmaceutics12020146.

Nanomedicine for respiratory diseases.

Bahadori M, Mohammadi F Tanaffos. 2014; 11(4):18-22.

PMID: 25191433 PMC: 4153217.

Cancer cell growth inhibitory effect of bee venom via increase of death receptor 3 expression and inactivation of NF-kappa B in NSCLC cells.

Choi K, Hwang C, Gu S, Park M, Kim J, Park J Toxins (Basel). 2014; 6(8):2210-28.

PMID: 25068924 PMC: 4147578. DOI: 10.3390/toxins6082210.

References

Wong H, Wu X, Bendayan R . Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2011; 64(7):686-700. DOI: 10.1016/j.addr.2011.10.007. View

Wohlfart S, Gelperina S, Kreuter J . Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2011; 161(2):264-73. DOI: 10.1016/j.jconrel.2011.08.017. View

Alexis F, Pridgen E, Molnar L, Farokhzad O . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-15. PMC: 2663893. DOI: 10.1021/mp800051m. View

Tomoda K, Ohkoshi T, Hirota K, Sonavane G, Nakajima T, Terada H . Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces. 2009; 71(2):177-82. DOI: 10.1016/j.colsurfb.2009.02.001. View

Weiss N, Miller F, Cazaubon S, Couraud P . The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2008; 1788(4):842-57. DOI: 10.1016/j.bbamem.2008.10.022. View

Kang K, Chun M, Kim O, Subedi R, Ahn S, Yoon J . Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine. 2010; 6(2):210-3. DOI: 10.1016/j.nano.2009.12.006. View

Choi S, Jin S, Lee M, Lim S, Park J, Kim B . Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur J Pharm Biopharm. 2007; 68(3):545-54. DOI: 10.1016/j.ejpb.2007.07.011. View

Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S . Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer. 2009; 68(2):240-7. DOI: 10.1016/j.lungcan.2009.06.017. View

Bridges E, Harris A . The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol. 2011; 81(10):1183-91. DOI: 10.1016/j.bcp.2011.02.016. View

10.

Ema M, Tanaka J, Kobayashi N, Naya M, Endoh S, Maru J . Genotoxicity evaluation of fullerene C60 nanoparticles in a comet assay using lung cells of intratracheally instilled rats. Regul Toxicol Pharmacol. 2012; 62(3):419-24. DOI: 10.1016/j.yrtph.2012.01.003. View

11.

Hun X, Zhang Z . Anti-epidermal growth factor receptor (anti-EGFR) antibody conjugated fluorescent nanoparticles probe for breast cancer imaging. Spectrochim Acta A Mol Biomol Spectrosc. 2009; 74(2):410-4. DOI: 10.1016/j.saa.2009.06.033. View

12.

Jain A, Jain S, Ganesh N, Barve J, Beg A . Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine. 2009; 6(1):179-90. DOI: 10.1016/j.nano.2009.03.002. View

13.

Grobmyer S, Zhou G, Gutwein L, Iwakuma N, Sharma P, Hochwald S . Nanoparticle delivery for metastatic breast cancer. Maturitas. 2012; 73(1):19-26. DOI: 10.1016/j.maturitas.2012.02.003. View

14.

de Mendoza A, Preat V, Mollinedo F, Blanco-Prieto M . In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release. 2011; 156(3):421-6. DOI: 10.1016/j.jconrel.2011.07.030. View

15.

Chow T, Lin Y, Hwang J, Wang H, Tseng Y, Pang V . Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol. 2008; 35(5):623-34. DOI: 10.1016/j.nucmedbio.2008.04.001. View

16.

Misra R, Acharya S, Sahoo S . Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today. 2010; 15(19-20):842-50. DOI: 10.1016/j.drudis.2010.08.006. View

17.

Yang S, Shieh M, Lin F, Lou P, Peng C, Wei M . Colorectal cancer cell detection by 5-aminolaevulinic acid-loaded chitosan nano-particles. Cancer Lett. 2008; 273(2):210-20. DOI: 10.1016/j.canlet.2008.08.014. View

18.

Garcia-Bennett A, Nees M, Fadeel B . In search of the Holy Grail: Folate-targeted nanoparticles for cancer therapy. Biochem Pharmacol. 2011; 81(8):976-84. DOI: 10.1016/j.bcp.2011.01.023. View

19.

Kaur I, Bhandari R, Bhandari S, Kakkar V . Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008; 127(2):97-109. DOI: 10.1016/j.jconrel.2007.12.018. View

20.

Zou W, Liu C, Chen Z, Zhang N . Studies on bioadhesive PLGA nanoparticles: A promising gene delivery system for efficient gene therapy to lung cancer. Int J Pharm. 2008; 370(1-2):187-95. DOI: 10.1016/j.ijpharm.2008.11.016. View